A RECENT meta-analysis has highlighted a significant relationship between psoriasis and metabolic syndrome (MetS), reinforcing the importance of integrated care for patients with this chronic skin condition. Psoriasis, an autoimmune disease characterised by red, scaly, and itchy skin lesions, is increasingly understood as a systemic disorder affecting more than just the skin.
The study analysed data from 12 separate studies involving 9,641 individuals with psoriasis, of whom 2,554 were diagnosed with MetS. The findings revealed that psoriasis patients face a 26.8% increased risk of developing MetS compared to those without psoriasis. This risk is markedly higher in patients with more severe psoriasis (PASI >10), where the likelihood of developing MetS more than doubles.
MetS is a cluster of metabolic abnormalities including abdominal obesity, hypertension, dyslipidaemia, and insulin resistance. It is strongly associated with increased risks of cardiovascular disease, diabetes, and other serious conditions. The researchers suggest that the chronic inflammation seen in psoriasis, driven by elevated levels of cytokines such as TNF-α, IL-6, and IL-22, plays a key role in disrupting metabolic processes.
Moreover, the bidirectional relationship between psoriasis and MetS was supported by evidence showing that metabolic disturbances can also exacerbate psoriasis symptoms. This cyclical interaction creates a clinical challenge, but also presents an opportunity for targeted intervention.
Experts recommend routine metabolic screening for psoriasis patients, particularly those with moderate-to-severe disease. Annual monitoring of glucose levels, lipid profiles, and blood pressure can aid in early detection of MetS. Integrated care approaches involving dermatologists, endocrinologists, and cardiologists are likely to yield the best outcomes.
Despite limitations such as the predominance of cross-sectional studies and potential geographic bias, this meta-analysis provides compelling evidence for a strong association between psoriasis and MetS. As biologic therapies for psoriasis advance, recognising and managing comorbidities like MetS becomes increasingly critical to improving long-term patient health and quality of life.
Reference
Li Z et al. The incidence of metabolic syndrome in psoriasis patients and its correlation with disease activity: a systematic review and meta-analysis. Front Med (Lausanne). 2025;12:1593003.
